Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01166061 |
Recruitment Status
:
Completed
First Posted
: July 20, 2010
Last Update Posted
: May 20, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans and animals, including asthma, allergic rhinitis, conjunctivitis and dermatitis. Worldwide, at least 40% of allergic patients are sensitized to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen.
ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy.
The purpose of the present study is to evaluate the safety and tolerability of multiple ascending doses of ToleroMune Grass in subjects allergic to grass.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Allergy | Biological: Placebo Biological: ToleroMune Grass | Phase 2 |
This study is designed as a randomised, double-blind, placebo-controlled study to evaluate the safety and tolerability of escalating multiple doses of ToleroMune Grass in subjects with a documented history of allergic rhinoconjunctivitis on exposure to grass. The efficacy of ToleroMune HDM will also be explored LPSR, EPSR, CPT and levels of grass specific IgE.
The study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 6 weeks before randomisation.
Period 2 (Treatment Period) will consist of 4 visits (Visits 3A-3D) four weeks apart. The first cohort will receive the lowest dose and successive dose groups will increasing doses of ToleroMune Grass, provided the first administration of the previous dose was safe and well tolerated.
In Period 3, 2 Post-treatment Challenge visits will take place, the first will be 2 weeks after the last administration in the Treatment Period and the second will be 17 weeks after the first administration. Follow-up will be conducted 3-10 days after the second PTC.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | An Escalating, Multiple-dose Study in Grass Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Grass |
Study Start Date : | July 2010 |
Actual Primary Completion Date : | April 2011 |
Actual Study Completion Date : | April 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1
Subjects to receive either active or placebo
|
Biological: Placebo
Solution resembling active solution but without peptides
Biological: ToleroMune Grass
1 x4 administrations 4 weeks apart
|
Experimental: Cohort 2
Subjects to receive either active or placebo comparator
|
Biological: Placebo
Solution resembling active solution but without peptides
Biological: ToleroMune Grass
1 x4 administrations 4 weeks apart
|
Experimental: Cohort 3
Subjects to receive either active or placebo comparator
|
Biological: Placebo
Solution resembling active solution but without peptides
Biological: ToleroMune Grass
1 x4 administrations 4 weeks apart
|
Experimental: Cohort 4
Subjects to receive either active or placebo comparator
|
Biological: Placebo
Solution resembling active solution but without peptides
Biological: ToleroMune Grass
1 x4 administrations 4 weeks apart
|
Experimental: Cohort 5
Subjects to receive either active or placebo comparator
|
Biological: Placebo
Solution resembling active solution but without peptides
Biological: ToleroMune Grass
1 x4 administrations 4 weeks apart
|
- Safety and tolerability of multiple intradermal injections of ToleroMune Grass in grass allergic subjects with allergic rhinoconjunctivitis [ Time Frame: Upto 22 weeks ]
- Area of Late Phase Skin Response [ Time Frame: Baseline and 14 weeks ]
- Area of Early Phase Skin Response [ Time Frame: Baseline and 14 weeks ]
- Change in CPT score [ Time Frame: Baseline and 4 weeks ]
- Grass specific IgG4 [ Time Frame: Baseline and 14 weeks ]
- Change in CPT score [ Time Frame: Baseline and 14 weeks ]
- Area of Early Phase Skin Response [ Time Frame: Baseline and 17 weeks ]
- Grass specific IgE [ Time Frame: Baseline and 17 weeks ]
- Area of Late Phase Skin Response [ Time Frame: Baseline and 17 weeks ]
- Change in CPT score [ Time Frame: 17 weeks after start of treatment ]
- Change in CPT score [ Time Frame: Baseline and 8 weeks ]
- Change in CPT score [ Time Frame: Baseline and 12 weeks ]
- Grass specific IgE [ Time Frame: Baseline and 14 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female, aged 18-65 years
- Minimum 2 year history of rhinoconjunctivitis on exposure to grass
- Positive skin prick test to whole grass allergen
- LPSR to whole grass allergen 8-10 hours after intradermal injection of greater than 35mm diameter response
- Positive CPT to whole grass allergen with a score ≥4
Exclusion Criteria:
- Subjects with a history of asthma
- Subjects with an FEV1 <80% of predicted
- Subjects with a rye grass specific IgE >100 kU/L
- Subjects with an acute phase skin response to whole grass allergen with a mean wheal diameter > 50 mm
- Subjects who score >1 for redness of conjunctiva or who have any watering or itchiness in the eye before administration of the CPT
- Treatment with beta-blockers, alpha-adrenoreceptor blockers, tranquillisers or psychoactive drugs
- History of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01166061
Canada | |
Centre de Recherche Appliqué en Allergie de Québec | |
Quebec, Canada, G1V 4M6 |
Principal Investigator: | Jacques Hebert, MD | Centre de recherche appliquée en allergie de Quebec |
Responsible Party: | Dr Rod Hafner, VP R&D, Circassia Ltd |
ClinicalTrials.gov Identifier: | NCT01166061 History of Changes |
Other Study ID Numbers: |
TG001 |
First Posted: | July 20, 2010 Key Record Dates |
Last Update Posted: | May 20, 2011 |
Last Verified: | May 2011 |
Keywords provided by Circassia Limited:
Grass Allergy Immunotherapy Rhinoconjunctivitis ToleroMune Grass |